BIOLYTX PHARMACEUTICALS CORP

Oklahoma City, OK · Biotech · Private

BP001, a peptide therapeutic derived from CAP37 for topical ophthalmic treatment of corneal infections and injuries

Claim this profile

Follows are private to you and power your alerts

Updated · biolytx.com

Sector
Biotech
Headquarters
Oklahoma City, OK
Latest Form D
$1.3M, Oct 2015
Total capital
$1.6M
Federal grants
$253K
1 award · 2020
Rank in peer group#206 of 392
Private capital raised
$1.3M
1 Form D · last Oct 2015
132 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

201520162017201820192020FEDERAL ↑EQUITY ↓Cumulative $1.6M$253K1st Form D$1.3M
201520162017201820192020FEDERAL ↑EQUITY ↓Cumulative $1.6M$253K1st Form D$1.3M

Latest events

  • Federal grantHealth and Human S · Phase I · Novel Ophthalmic Product for Corneal Infections and Injuries$253K
  • Private capital raisedForm D · SEC · 1st filing$1.3M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 392 peers

Line = median

Biotech · Molecule

  • Federal grantsBelow median

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • Douglas A BranchExecutive OfficerNamed in SEC Form D filings
  • H Anne PereiraExecutive Officer, DirectorNamed in SEC Form D filings
  • William A HagstromDirectorNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .